potential indications for glp-1 receptor agonists keep expanding in Cardiovascular Diseases: Mechanisms, Clinical Evidence, and Emerging Therapies Mapping the effectiveness and risks

9amHealth was founded in 2021 by the team behind mySugr and is backed by 7Wire Ventures, Cigna Ventures, Human Capital, Founders Fund, and Define Ventures

Both the pharmacovigilance findings and the case series indicated that liraglutide and dulaglutide were the leading suspected GLP-1 RAs, and pharmacovigilance analysis showed that exenatide had the highest number of ICSRs associated with AP

This also applied to another five ongoing studies identified (Supplementary Section 3)

Tirzepatide, a dual GIP/GLP1-receptor co-agonist preserves cardiac function and improves survival in angiotensin II-induced heart failure model in mice: comparison to liraglutide

The patent landscape reflects intense focus on permeation enhancers, solid oral compositions, and buccal or sublingual alternatives to injection [7, 8, 9]

GLP-1 is a hormone that is involved in normalizing the level of glucose in blood (glycemia)